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Comorbidities have been demonstrated to affect progression-
free survival (PFS) and overall survival (OS), although their
impact in multiple myeloma (MM) patients is as yet unsettled.
We (1) assessed various comorbidities, (2) compared estab-
lished comorbidity indices (CIs; Charlson comorbidity index
(CCI), hematopoietic cell transplantation-speciﬁc comorbidity
index (HCT-CI)), Kaplan Feinstein (KF) and Satariano index (SI)
and (3) developed a MM-CI (Freiburger comorbidity index, FCI)
in 127 MM patients. Univariate analysis determined moderate or
severe pulmonary disease (hazard ratio (HR): 3.5, Po0.0001),
renal impairment (via estimated glomerular ﬁltration rate
(eGFR); HR: 3.4, P¼0.0018), decreased Karnofsky Performance
Status (KPS, HR: 2.7, P¼0.0004) and age (HR: 2, P¼0.0114) as
most important variables for diminished OS. Through multi-
variate analysis, the eGFR p30ml/min/1.73m
2, impaired lung
function and KPS p70% were signiﬁcant for decreased OS,
with HRs of 2.9, 2.8 and 2.2, respectively. Combination of these
risk factors within the FCI identiﬁed signiﬁcantly different
median OS rates of 118, 53 and 25 months with 0, 1 and 2 or 3
risk factors, respectively, (Po0.005). In light of our study,
comorbidities are critical prognostic determinants for dimin-
ished PFS and OS. Moreover, comorbidity scores are important
treatment decision tools and will be valuable to implement into
future analyses and clinical trials in MM.
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Introduction
Despite today’s novel therapeutic options,
1,2 multiple myeloma
(MM) remains an incurable disease in the majority of patients
with highly variable outcome, depending on various risk
factors.
2,3 The classiﬁcation of MM is based on Salmon and
Durie (S&D) and International Staging System, including
primarily disease-related risk. Nevertheless, patient-related
factors, like comorbidities and abnormal organ function,
describing additional hazards on outcome, are not as yet
integrated in prognostic models. Risk models are of importance,
however, as myeloma patients are typically in their sixth to
seventh decade of life and often fragile. As numerous treatment
options with differing intensity have also become available,
4 this
adds to the current complexity to choose the best therapeutic
option for deﬁned patients. Prior studies have shown that
comorbidities have substantial impact on overall survival (OS),
such as in patients with myelodysplastic syndromes,
5–7 acute
myeloid leukemia
8,9 or for allogeneic stem cell transplantation
(SCT).
10 As not all comorbidities may affect the outcome, risk
factors within these scores are often weighted according to their
severity;
11 nevertheless, whether these hazards are equally
important in different diseases and patient groups are unsettled.
Renal impairment as one essential comorbidity occurs in
20–40% of myeloma patients, depending on the deﬁnition of
renal function.
12,13 As compared with the estimated glomerular
ﬁltration rate (eGFR), serum creatinine is inﬂuenced by multiple
factors, exposes limits to detect mild and moderate renal
impairment
14,15 and differs among individuals. For these
reasons, the relationship between creatinine and GFR varies
substantially and creatinine values exceed those of the GFR.
15
Therefore, the National Kidney Foundation–Kidney Disease
Outcomes Quality Initiative and International Myeloma Work-
ing Group recommend estimating the GFR via ‘Modiﬁcation of
Diet in Renal Disease’ equation.
16,17
We and others have previously conﬁrmed the prognostic
importance of renal impairment for diminished progression-free
survival (PFS) and OS in cancer patients in general and in MM
patients in particular.
13,14,18,19 Moreover, we have shown that
advanced stage, elevated beta-2 microglobulin, deteriorated
Karnofsky Performance Status (KPS), and comorbidities repre-
sent univariate risk factors in MM.
18,20,21 As cancer patients with
comorbidities are often excluded from clinical trials, and there is
little evidence how to translate results from cooperative studies
to older or frail patients, it is increasingly recognized that
well-performed cohort analyses are important, reﬂecting a more
typical rather than highly selected patient group. To further
understand the role and impact of comorbidities and primary
disease on patient outcome,
18,22 we here (1) determined the
value of single risk factors, (2) compared established comorbid-
ity indices (CIs) and (3) developed a simply assessable
MM–comorbidity score, these assessments recently being
attributed as highly important for myeloma patients.
23
Materials and methods
Patient description and study design
After approval by the departmental review board, individual
consecutive MM patients treated at our institution between
January 1997 and July 2003 were retrieved from our electronic
database system for tumor documentation.
24 Patient data
included age, KPS, hypertension, diabetes, secondary malig-
nancies, pain, liver, heart and lung disease, renal impairment,
and other relevant concomitant conditions. Deﬁnition of various
comorbidities was performed as described (Supplementary
Methods). The analysis was carried out according to the
guidelines of the Declaration of Helsinki Principles and Good
Clinical Practice. All patients gave their written informed Received 7 June 2011; accepted 7 July 2011
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Treatment schedule
Patients were treated with standard chemotherapy or autologous
SCT (ASCT) according to our institutional MM pathway.
1
Patients not eligible for autologous SCT received MP-thalido-
mide (melphalan 0.25mg/kg, days 1–4, prednisone 2mg/kg,
days 1–4, thalidomide 100mg/day), MP alone or high-dose
dexamethasone.
1 Autologous SCT was recommended for
medically ﬁt, symptomatic patients up to the age of 70 years.
Induction consisted of four ID cycles (idarubicin 8mg/m
2,
dexamethasone 20mg/m
2 days 1–4, 9–12, 17–19) within the
German Study group (DSMM V) trial. Mobilization (epirubicin
100mg/m
2 day 1, etoposide 150mg/m
2 days 1–3, ifosfamide
2500mg/m
2 days 1–3) and conditioning (melphalan 200mg/m
2
or 140mg/m
2 with creatinine values 42.0mg/dl) was
performed as described.
1,2
Statistical analysis
Data analyses were performed using the SAS statistical software
version 9.1. (SAS Institute Inc., Cary, NC, USA). Comparisons of
binary variables were conducted by means of continuity
adjusted w
2-tests; for continuous variables, Wilcoxon’s
two-sample tests were used. A P-value of o0.05 was considered
as statistically signiﬁcant. Overall survival was deﬁned as the
time from diagnosis to death from any cause, and PFS as the
time from diagnosis to death from any cause or cancer
recurrence. Data for patients alive (alive without recurrence,
respectively) at the time of the analysis were censored at the last
follow-up. Probabilities of PFS and OS were calculated using
Kaplan–Meier estimator for each variable. Univariate Cox
proportional hazards regression models were performed to
evaluate the prognostic signiﬁcance of each comorbidity factor
and results are presented as estimated hazard ratios (HRs) with
95% conﬁdence intervals. To include sufﬁcient patients, lung
disease, KPS, cardiac disease and eGFR were summarized from
initially three or four patients into two groups. Prognostic factors
showing a univariate Po0.1 were entered in a multivariate Cox
model. Moreover, a non-weighted prognostic model (sum score)
was constructed, whereby HR and Kaplan–Meier curves with 0
to 3 risk factors were assessed.
We also compared the Charlson comorbidity index (CCI),
25
hematopoietic cell transplantation-speciﬁc CI (HCT-CI),
10
Kaplan Feinstein (KF)
26 and Satariano index (SI).
27 Their
deﬁnition, development, comorbid conditions, weighted vs
non-weighted status and rating differences are summarized in
Supplementary Table 1. We thereby (1) compared CIs that
predict OS in hematological malignancies (CCI), or as assessed
for SCT recipients (HCT-CI); (2) included weighted (KF, CCI,
HCT-CI) vs non-weighted scores (SI) and (3) evaluated
differently scored CIs (KF assigns the highest comorbidity to an
end-score, whereas CCI, HCT-CI and SI add their comorbidities
to a sum score). We analyzed median comorbidity scores of
each CI and determined PFS and OS differences in ‘low-risk’ vs
‘high-risk’ patients (scoring p vs 4 median CI points).
Results
Patient characteristics
In our patients, immunoglobulin G was the most common
myeloma type, 17% had light-chain MM and 1% had
non-secretory MM. Stages II/III disease by Salmon and Durie
or International Staging System was present in 91% and 41%,
respectively, and stage B disease was found in 15% of the
patients. Although the creatinine levels appeared normal with
0.8mg/dl, the median eGFR was decreased with 88ml/min/
1.73m
2, corresponding to chronic kidney disease (CKD) stage 2.
Of note, 51% of patients were in CKD stages 2–5 and 27% in
CKD stages 3–5. Our MM patients showed a median age of
60 years (range: 27–83 years; Table 1). Median PFS and OS were
2.9 and 5.8 years, respectively.
Table 1 Patient characteristics (n¼127)
Variables n (%) Median (range)
Age (years) 60 (27–83)
Sex, M: F 70 (55): 57 (45)
Type of myeloma
IgG 67 (52)
IgA 31 (24)
IgM 2 (2)
IgD 2 (2)
Biclonal (G, A) 2 (2)
Light-chain MM 22 (17)
Non-secretory 1 (1)
Kappa/lambda 81 (64)/45 (36)
Intramedullary/extramedullary 118 (93)/9 (7)
AL/AH amyloidosis 2 (2)
Salmon and Durie stage
I 11 (9)
II/III 116 (91)
A/B 108 (85)/19 (15)
ISS stage (n¼75)
I 44 (59)
II 11 (15)
III 20 (26)
KPS (%) 90 (40–100)
BMI (kg/m
2) 24 (15–36)
Beta-2 microglobulin (mg/dl) 79 (62) 3 (1.1–23)
PC BM inﬁltration rate (%) 72 (57) 31 (0–90)
Creatinine (mg/dl) 0.8 (0.4–7.4)
eGFR (MDRD, ml/min/1.73m
2) 88 (6–182)
CKD stages
1: eGFR X90ml/min/1.73m
2 62 (49)
2: eGFR 89–60ml/min/1.73m
2 31 (24)
3: eGFR 59–30ml/min/1.73m
2 22 (17)
4: eGFR 29–15ml/min/1.73m
2 6 (5)
5: eGFR o15ml/min/1.73m
2 6 (5)
Cytogenetics (FISH) 56 (44)
Deletion 13q14 16 (29)
Standard therapy : auto PBSCT 65 (51): 62 (49)
Abbreviations: AH, amyloid heavy; AL, amyloid light; auto-PBSCT,
autologous peripheral blood stem cell transplantation; BMI, body mass
index; CKD, chronic kidney disease stages according to the K/DOQI
guidelines deﬁned by MDRD; eGFR, estimated glomerular ﬁltration
rate; F, female; FISH, ﬂuorescent in situ hybridization; Ig, immuno-
globulin; ISS, International Staging System; KPS, Karnofsky Perfor-
mance Status; M, male; MDRD, Modiﬁcation of Diet in Renal Disease;
MM, multiple myeloma; PC BM inﬁltration rate, plasma cell
bone marrow inﬁltration rate; estimated GFR (ml/min/1.73m
2)¼
186 (serum creatinine level (in milligrams per decilitre))
 1.154 (age
(in years))
 0.203 (0.742, if female, 1.21, if black).
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We evaluated comorbid conditions in their speciﬁc
frequency, similarly as assessed in various CIs (Figure 1a).
Pain (57%) and a diminished KPS (30%) showed frequent
impairment. Other common comorbidities were cardiac (20%),
lung (18%) and liver disease (16%), hypertension (16%),
diabetes (10%) and renal impairment (10%). Additional
malignancies occurred in 6% of the patients.
28 All of our
assessed comorbidity conditions are also captured in the KF,
HCT-CI, CCI and SI, except for pain (Figure 1a, Supplementary
Table 1).
Of note, univariate analysis proved that only pulmonary, renal
and KPS impairment, and age were signiﬁcant for both PFS and
OS (Table 2). Additional malignancies signiﬁcantly impaired
PFS, but did not substantially decrease OS.
28 Hepatic or cardiac
disease, hypertension, pain or diabetes did not substantially
diminish PFS or OS (Table 2).
Multivariate analysis and risk stratiﬁcation via
Freiburger comorbidity index
After variable selection, the KPS p70%, moderate or severe lung
disease and eGFRo30ml/min/1.73m
2 were most relevant multi-
variate factors for OS (Table 3). On the basis of the univariate and
multivariate results, a prognostic model was generated, combining
the KPS, lung impairment and eGFR in a sum score (Freiburger
comorbidity index; FCI). This allowed to deﬁne largely different
groups: with 0, 1 and 2 or 3 risk factors, HR substantially
increased from 1 to 2.5 and 6.5 and median OS was 118, 53 and
25 months, respectively, (Table 3 and Figures 1b and c).
Systematic comparison of various CIs and PFS/OS
in ‘low-risk’ vs ‘high-risk’ groups
Of our 10 risk factors, as assessed via univariate and multivariate
analyses, (Table 2), 8 out of 12 comorbidities are also scored
Figure 1 Analysis of comorbidities, and survival with different comorbidity scores in MM patients. (a) Distribution of speciﬁc comorbidities and
patient characteristic features. Pain (57%) and a diminished KPS (30%) were most frequently impaired attributes in our MM cohort. Common organ
comorbidities were cardiac (20%), lung (18%) and moderate-to-severe liver disease (16%), hypertension (16%), diabetes (10%) and renal
impairment (10%). Additional malignancies occurred in 6%. Age X60 years was present in 49% of the patients. All of our assessed comorbidity
conditions are also captured in the KF, HCT-CI, CCI and SI, accept for pain (see also Supplementary Table 1). (b) On the basis of our univariate and
multivariate results, a prognostic model was constructed, combining the KPS (p70%), lung impairment and eGFR (o30ml/min/1.73m
2)i na
comorbidity sum score (FCI). This allowed to deﬁne largely different patient groups: OS was signiﬁcantly different among patients with no ( ),
1( ), 2 or 3 ( ) risk factors, with median survival times of 118 (n¼74), 53 (n¼36) and 25 months (n¼17), respectively, (P¼0.0033 and
Po0.0001). (c) FCI stratiﬁcation into two patient risk groups: OS was again signiﬁcantly different in patients with no ( ) vs 1–3 ( ) risk factors, with
median OS of 117 (n¼74) vs 41 months (n¼53, Po0.0001), respectively. (d–g) OS differences of low-risk vs high-risk patients as stratiﬁed via
HCT-CI (d), KF (e), SI (f) and CCI (g). The differences among risk groups as scored via HCT and KF were signiﬁcant (Po0.05), whereas via SI and
CCI less distinctive. (h) The established four CIs (KF, HCT-CI, SI and CCI) are compared with the FCI. The number of weighted factors is given
behind each comorbidity factor. The number of evaluated comorbidities in our univariate and multivariate analyses that led to the FCI covered 8/
12, 10/17, 10/20 and 7/7 comorbidities as included in the established KF, HCT-CI, CCI and SI, respectively. The ﬁgure depicts why the FCI, KF and
HCT-CI were more valuable in MM than in SI: the KF includes the appraisal of a reduced KPS (K), lung disease (L) and renal impairment (e) that
were all highly valuable in our MM cohort; both the HCT-CI and CCI also include lung disease and renal impairment in their score, whereas the SI
includes only lung impairment in its comorbidity assessment.
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Blood Cancer Journalwithin the KF, 10 out of 17 in the HCT-CI, 10 out of 20 in the
CCI and all seven in the SI.
Median scores in our cohort were from 0 to 1 for the FCI,
HCT-CI and SI, 2 for the KF and 5 for the CCI (Table 4), the latter
because of the assignment of two points for the presence of a
concomitant hematologic malignancy and inclusion of age.
To facilitate comparisons, all CIs were also collapsed
into two groups (‘low-risk’ vs ‘high-risk’; Table 4 and
Table 2 Univariate analysis of prognostic factors on PFS and OS
Comorbidity Deﬁnition n Median PFS
(months)
P-value
a Median OS
(months)
P-value
a HR (95%
Conﬁdence interval)
P-value
a
Lung disease No/mild 104 43 0.0014 103 o0.0001 3.47 (2–6.14)
c o0.0001
c
Moderate 13 21 37
Severe 10 11 25
eGFRMDRD (ml/min/1.73m
2) X90 60 50 0.005 98 0.0008 3.44 (1.58–7.49)
c 0.0018
c
60 to o 90 38 35 63
30 to o 60 17 22 30
o 30 12 15 15
KPS 100% 35 61 o0.0001 F 0.0003 2.69 (1.56–4.63)
c 0.0004
c
80–90% 53 33 98
p 70% 39 27 41
Age (years) p59 65 61 0.0003 98 0.01 1.99 (1.17–3.41) 0.0114
459 62 26 53
Additional malignancy
apart from MM
b
No 119 36 0.0041 69 0.9605 1.04 (0.25–4.28) 0.9599
Yes 8 10 F
Hepatic impairment No/mild 107 36 0.5081 76 0.6328 1.18 (0.6–2.35) 0.6331
Moderate/severe 20 27 69
Cardiac impairment No/mild 102 36 0.5299 76 0.997 1.01 (0.52–1.95)
c 0.9831
c
Moderate 10 27 46
Severe 15 35 62
Hypertension No 106 35 0.7161 76 0.5949 0.81 (0.36–1.79) 0.5958
Yes 21 33 63
Pain No 54 50 0.5038 98 0.2105 1.41 (0.82–2.41) 0.2127
Yes 73 32 60
Diabetes No 114 35 0.8145 69 0.9782 0.99 (0.36–2.74) 0.9783
Yes 13 45 60
Abbreviations: eGFR, estimated glomerular ﬁltration rate; HR, hazard ratio; KPS, Karnofsky Performance Status; MDRD, Modiﬁcation of Diet in
Renal Disease; MM, multiple myeloma; OS, overall survival; PFS, progression-free survival.
aLog-rank test.
bAny additional malignancy, apart from the MM, occurring prior, synchronous or after the MM diagnosis, which because of any of the 8 out of the
127 MM patients with additional malignancy, was not further subdivided within these groups.
cThese risk factors were summarized as two groups: lung disease, no/mild vs moderate/severe; eGFR o30 vs X30ml/min; KPS: 470 vs p70%;
cardiac impairment, no/mild vs moderate/severe.
Table 3 Multivariate analysis of prognostic factors and risk stratiﬁcation by combination of KPSp70%, moderate or severe lung disease
and eGFRo30
Comorbidity factors Deﬁnition n HR (95% Conﬁdence interval) P-value
a
KPS 470% 88 2.17 (1.23–3.82) 0.0077
p70% 39
Lung disease No/mild 104 2.78 (1.53–5.04) 0.0008
Moderate/severe 23
eGFRMDRD (ml/min/1.73m
2) X30 115 2.93 (1.33–6.46) 0.0075
o30 12
FCI Median OS (months) n HR (95% Conﬁdence interval) P-value
a
0 118 74 1.0 (reference) F
1 53 36 2.5 (1.4–4.5) 0.0033
2 or 3 25 17 6.5 (3.2–13.2) o 0.0001
Abbreviations: eGFRMDRD, estimated glomerular ﬁltration rate by MDRD (Modiﬁcation of Diet in Renal Disease); FCI, Freiburger comorbidity index;
HR, hazard ratio; KPS, Karnofsky Performance Status; OS, overall survival.
aw
2-test.
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Blood Cancer JournalFigures 1b–g): ‘low-risk’ patients revealed substantially longer
PFS and higher OS rates than ‘high-risk’ patients. Survival
differences reached signiﬁcance via HCT-CI, KF, CCI and FCI for
PFS, and via HCT-CI, KF and FCI also for OS. The SI proved least
valuable (Figures 1b–g).
Figure 1h depicts the FCI as compared with the other
established CIs, illustrating why the FCI, KF, HCT-CI and CCI
seemed more valuable in MM: the KF also scores the KPS, lung
and renal impairment, risks that were especially valuable in this
analysis. Both HCT-CI and CCI include lung and renal
impairment, whereas the SI includes only lung impairment in
its risk assessment. Thus, the cautious comparison of the FCI
with the four well-known CIs suggested that the FCI allows risk
prediction for PFS and OS equally well as the HCT-CI and KF,
with the advantage of the former to be effortlessly assessable.
Patient characteristics in different age categories
Patients were grouped into three age categories of o60, 60–69
and X70 years (Supplementary Table 2). Patients with higher
age showed stage B disease more often (in line with increasing
patients with eGFRo30) and rising beta-2 microglobulin levels.
Moreover, cardiac impairment (16%, 20%, 29%), hypertension
(11%, 18%, 29%), diabetes (7%, 11%, 19%) and pain (41%,
53%, 83%, respectively) increased. Of note, moderate or severe
lung disease and hepatic impairment did not substantially
enlarge within higher ages.
Of note, ‘high-risk’ patients as scored with the FCI, HCT-CI
and KF decreased in the age category of X70 years. In contrast,
‘high-risk’ patients scored via SI and CCI increased with age, the
latter more substantial due to the inclusion of age as an
additional weighted condition with extra points for every age
decade starting at 50 years. The increase of ‘high-risk’ patients
with use of the SI could be related to the fact that this CI covers
especially age-dependent comorbidities.
Organ function and comorbidity according to treatment
Although peripheral blood SCT and standard therapy were not
stratiﬁed to be compared in this analysis, both therapeutic
options are depicted in Supplementary Table 3. Patients
receiving standard therapy were older and showed a decreased
KPS. The median eGFR was 76 vs 107ml/min/1.73m
2, res-
pectively. Cardiac impairment, hypertension, diabetes mellitus,
hepatic impairment and pain were similar in both groups.
‘High-risk’ CI patients were increased in patients receiving
standard therapy, although only via FCI, HCT-CI, CCI and KF,
these differences were most substantial, but not via SI.
Patient characteristics within CKD stages
Comparison of CKD stages 1–2, 3 and 4–5 revealed that age,
impaired KPS, beta-2 microglobulin and some other comorbid-
ities (lung and cardiac impairment, hypertension) increased with
renal deterioration, whereas this was less prominent for diabetes
or hepatic impairment.
Patients deﬁned as ‘high-risk’ because of X median CI scores
assessed via FCI, HCT-CI, CCI, KF and SI increased with higher
CKD stages, although the SI showed the less noticeable effect,
due to the fact that renal function is not included. These
observations highlight that with increasing renal impairment in
MM additional underlying comorbidities were also evident
(Supplementary Table 4).
Discussion
Numerous risk features have been evaluated in MM to improve
its prognostic appraisal, and predictive markers are eagerly
tested worldwide.
29–32 Apart from organ function,
14,18 also
comorbidity assessment in other diseases,
7,10,33–35 but not in
MM, has been acknowledged as important. This has recently
been stressed,
23 as there is a vastly enlarged arsenal of treatment
options for MM patients today, so that comorbidity assess-
mentsFbeside disease-related risk factorsFmay immensely
assist in the allocation of available therapies. Especially in case
of stratiﬁcation between standard, intensive or clinical trial
options, clinical judgment by the physician and patient
preference require standardized decision tools to balance the
treatment proﬁts and risks of toxicity.
Traditionally, risk classiﬁcations in MM are based on disease-
related factors, although patient-related factors, such as
impaired performance status or organ function, may also
inﬂuence outcome,
31,36 this being highly relevant as MM
develops primarily in elderly patients. Our observations
demonstrated the high impact of patient-related conditions as
additional risks in MM: in line with our and prior data,
37,38 we
could identify renal impairment as most inﬂuential for survival,
followed by lung and KPS impairment. Lung impairment has
previously been described to affect survival
39 and to be
Table 4 PFS and OS of various analyzed comorbidity indices (HCT-CI, KF, SI, CCI and FCI) in ‘low-risk’ vs ‘high-risk’ scoring patients
Score Maximum
score
Median
score (range)
n Low-risk vs
n high-risk
a
Median PFS
(months)
P-value
b Median OS
(months)
P-value
b
HCT-CI 26 1 (0–10) Low¼78 46 0.001 98 0.002
High¼49 24 44
KF 3 2 (0–3) Low¼88 45 0.0016 81 0.007
High¼39 24 41
SI 7 1 (0–4) Low¼94 39 0.0838 77 0.0876
High¼33 22 60
CCI 33 + age 5 (2–12) Low¼89 50 0.003 76 0.4159
High¼38 29 60
FCI 3 0 (0–3) Low¼74 51 0.0003 117 o0.0001
High¼53 25 41
Abbreviations: CCI, Charlson comorbidity index; FCI, Freiburger comorbidity index; HCT-CI, hematopoietic cell transplantation-speciﬁc comorbidity
index; KF, Kaplan Feinstein; OS, overall survival; PFS, progression-free survival; SI, Satariano index.
aLow score: pmedian, high score: 4median.
bLog-rank test.
A P-value o0.05 was considered as statistically signiﬁcant.
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40 KPS has been identiﬁed as
crucial for patient outcome in various diseases,
41 underlining its
value to be accurately recorded.
18,41
Previous trials have also assessed the impact of advanced age
on survival,
20,21 this being linked to higher age-related
comorbidities and diminished functional status.
21 This is
relevant, as the impact of age becomes increasingly important
with age escalation.
21,42,43 Of interest in our multivariate
analysis was that age proved less signiﬁcant as compared with
renal, KPS or lung impairment, and that the comparison of
different age groups revealed that speciﬁc risks can be easily
over- or underestimated and that age alone may be an
insufﬁcient decision tool for anti-MM treatment. Our data
illustrated well that biological age can substantially differ from
the chronological patient age and why age was a univariate, but
not multivariate risk in our analysis. One may argue that age was
found less relevant, because our median patient age was
60 years, which relates typically to large university and referral
centers. Although we cannot exclude diminished statistical
power to detect a more substantial age impact because of
limited patient numbers in much older cohorts, more than half
of our patients were older than 60 years and approximately 20%
even X70 years.
Besides our assessment of prognostic conditions, different
comorbidity scores were also thoroughly evaluated. Among
these, the CCI and HCT-CI are widely used to predict outcome
in hematological malignancies,
7,41 in line with our results that
the CCI proved signiﬁcant for PFS, and the HCT-CI for both PFS
and OS. Farina et al.
41 conﬁrmed that the HCT-CI predicts PFS
and OS in lymphoma patients after reduced intensity condition-
ing allogeneic SCT. Another study has demonstrated the utility
of the CCI and HCT-CI for predicting transplantation-related
toxicity and prolonged hospital stay.
40 In addition, renal
impairment is assessed in the HCT-CI, which was of importance
in this and our previous analyses.
14,18 Interestingly, the CCI
revealed a lesser predictive power than the HCT-CI. Explana-
tions for their different OS impact are that the HCT-CI has been
developed from the CCI and established in hematologic
malignancies, whereas the CCI has been used in various, rather
than speciﬁc diseases.
10 Another reason for the increased
sensitivity and speciﬁcity of the HCT-CI to predict patient
outcome, including in transplant candidates, is the enhance-
ment of comorbidity deﬁnition, particular in adding pulmonary
and liver function test with higher weights compared with the
CCI.
10 As pulmonary disorders are profoundly weighted in the
HCT-CI, this explains its predictive value in our MM cohort also.
Besides the HCT-CI, the KF was valuable for survival in our
cohort, this most likely being related to the inclusion of patients’
performance status, lung and renal impairment, as well as
grading the derangement.
44,45 The use of our FCI allowed to
deﬁne distinct risk groups: with 0, 1 and 2 or 3 risk factors, OS
was substantially different with 118, 53 and 25 months,
respectively. In terms of risk allocation in ‘low-risk’ vs ‘high-
risk’ patients, the cautious comparison of the FCI with the four
other CIs revealed most striking group differences for the FCI,
HCT-CI and KF and least valuable group distinction for the CCI
and SI. We could thereby highlight that speciﬁc CIsFnamely
the FCI, HCT-CI and KFFbest reﬂect MM patients’ performance
status and organ function, and that the chronological age alone
may fail to predict the clinical outcome.
23
Our analysis represents the ﬁrst systematically performed
organ and functional assessment in myeloma patients, and
includes the ﬁrst comparative evaluation of four previously
established CIs in MM. We created a new risk assessment tool in
MM, as previously established CIs were developed for entirely
different diseases. Translating the organ and functional status
into a novel, simply assessable FCI, which we developed
independently of the performed myeloma treatment, allowed to
deﬁne three distinct risk groups with largely different OS.
However, the validation of this approach and utility in routine
use has to be further investigated in prospective and randomized
studies in terms of therapy-related toxicity, lengths of hospital
stay and survival. Nevertheless, the primary purpose of this
analysis was to introduce a new sum score of risk factors to
predict outcome in MM, which was successfully accomplished.
The direct comparison of the FCI with the four established CIs
may be criticized, as the assessed comorbidities do not cover all
derangements as included in the other scores, and the FCI needs
to be reassessed in an independent training and test sets, which
is underway. Another criticism may cover the use of different
therapies that can interact with speciﬁc risks, although we
intentionally aimed to determine a treatment-independent risk
score that can be utilized in various treatment groups. Finally,
evaluation of various cytogenetic abnormalities as important
molecular risks needs to be included in subsequent analyses.
We conclude that the present study provides an initial important
step for the utilization of comorbidity assessment in MM and
should facilitate treatment decision-making in the near future. We
suggest that assessing the comorbidity status in MM, rather than
considering speciﬁc age cutoffs alone, may allow to better deﬁne
patients’ status, tolerability of treatment and to learn about best
treatment allocations in upcoming patient cohorts.
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